AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Wyeth informs physicians of WHI findings.(Women's Health Initiative Study)

Women's Health Weekly

| August 22, 2002 | COPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2002 AUG 22 - (NewsRx.com & NewsRx.net) -- Wyeth Pharmaceuticals is informing healthcare providers of important results on combination hormone replacement therapy (HRT) from the Women's Health Initiative Study (WHI).

Results from this trial provide physicians and the public with more definitive information regarding the risks and benefits associated with the long-term use of estrogen plus progestin therapy (or combination HRT).

However, the study did not evaluate the use of combination HRT for the treatment of menopausal symptoms or vaginal atrophy.

"These are valuable new data with significant implications. However, it is also important to recognize the critical role that combination HRT plays in treating the symptoms of menopause, the number one reason that women start therapy," said Victoria Kusiak, MD, vice president, clinical affairs and North American medical director. In a recent survey, doctors report that management of symptoms is a treatment goal for 9 out of 10 new patient starts with combination HRT.

In the WHI trial, the primary endpoints were prevention of coronary heart disease and the incidence of breast cancer. The study found that combination HRT increased the risk of cardiovascular disease (CVD) and, over time, increased the risk of breast cancer. The WHI also found that combination HRT reduced the risk of hip and other fractures and reduced the risk of colon cancer.

The National Institutes of Health (NIH) discontinued the combination HRT arm of the WHI due to the increased risk of invasive breast ...

Related articles from newspapers, magazines, journals, and more
Wyeth Informs Physicians of WHI Findings; - Company Reaffirms Role of...
Press release article from: PR Newswire July 9, 2002 700+ words
...incidence of breast cancer. The study found that combination HRT increased...the risk of breast cancer. The WHI also found that combination HRT reduced the...about the breast cancer and cardiovascular...labeling for combination HRT products...
Studies confirm adverse effects of combination HRT: more WHI data:...
Magazine article from: OB GYN News Brunk, Doug September 15, 2003 700+ words
...investigators for using just one combination HRT product (Prempro...increased risk for invasive breast cancer, and that the relative risk of breast cancer in current users increases...364 cases of invasive breast cancer and 637 breast cancer...
Combination HRT linked to dementia in older women: findings reinforce need to...
Magazine article from: OB GYN News Tucker, Miriam E. July 1, 2003 700+ words
...before and since last summer's early release of the primary WHI data showing that combination therapy increased the risks of breast cancer and stroke (JAMA 288[3]3:321-33, 2002). The NAMS paper will be released at the society's meeting this fall...
Noven Announces Presentation of Data On Effect of Transdermal Combination HRT...
Press release article from: Business Wire June 11, 2002 700+ words
...developer of advanced transdermal drug delivery technologies and prescription transdermal products, including the only combination HRT patch available in the United States. For additional information on Noven, visit http://www.noven.com.
Noven Signs Product Development Agreement With Novartis; Work Underway on...
Press release article from: Business Wire August 2, 2001 700+ words
...new development agreement underscores Novartis Pharma's commitment to establishing and, importantly, maintaining our combination HRT patch as a leading product line," said Robert C. Strauss, Noven's President, CEO and Chairman. "It also helps confirm...
Oral Combination HRT May Benefit Diabetic Women.(hormone replacement therapy )
Magazine article from: Family Practice News Tucker, Miriam E. August 1, 2000 700+ words
SAN ANTONIO -- Oral combination hormone replacement therapy appears to confer metabolic benefits to women with type 2 diabetes--benefits not seen with the transdermal formulation, Dr. Daniel A. Darko said at the annual scientific session of the American Diabetes Association. In an open-label trial
Fact sheet on hormone replacement therapy and breast cancer.
Magazine article from: The Network News Zones, Jane Sprague November 1, 2002 700+ words
Estrogen/Progestin Combination HRT Causes Breast Cancer On July 9, 2002, officials...had been found to cause breast cancer in previously healthy women...possible increased risk of breast cancer in an effort to finally determine...
Adding Progestin to Estrogen Multiplies Breast Cancer Risk.(Brief Article)
Magazine article from: Family Practice News JANCIN, BRUCE March 15, 2001 700+ words
...a modest 7% increase in breast cancer risk. In contrast, 5 years...therapy (HRT) increased breast cancer risk by 29%--more than...suggesting that women on combination HRT who develop breast cancer should have a relatively...
For more facts and information, see all results

Source: HighBeam Research, Wyeth informs physicians of WHI findings.(Women's Health Initiative...

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA